Eli Lilly and Company (NYSE:LLY) Shares Bought by Sterling Financial Planning Inc.

Sterling Financial Planning Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 2.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 857 shares of the company’s stock after buying an additional 20 shares during the quarter. Sterling Financial Planning Inc.’s holdings in Eli Lilly and Company were worth $500,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of LLY. JGP Wealth Management LLC boosted its position in Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after acquiring an additional 16 shares during the period. Cassia Capital Partners LLC lifted its holdings in shares of Eli Lilly and Company by 1.8% during the third quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock worth $511,000 after buying an additional 17 shares during the last quarter. Walkner Condon Financial Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 2.8% during the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after buying an additional 17 shares during the last quarter. Patton Albertson Miller Group LLC raised its stake in shares of Eli Lilly and Company by 2.8% in the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after purchasing an additional 17 shares in the last quarter. Finally, Valley Wealth Managers Inc. raised its stake in shares of Eli Lilly and Company by 1.3% in the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.6 %

Shares of NYSE LLY traded down $4.82 during mid-day trading on Thursday, reaching $745.95. 1,701,145 shares of the company’s stock were exchanged, compared to its average volume of 3,067,708. The business has a fifty day simple moving average of $764.03 and a 200 day simple moving average of $657.67. Eli Lilly and Company has a twelve month low of $367.35 and a twelve month high of $800.78. The firm has a market capitalization of $708.77 billion, a price-to-earnings ratio of 129.32, a PEG ratio of 1.63 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.09 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on LLY shares. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. BMO Capital Markets increased their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Finally, Truist Financial restated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.